Gilead slides 4% after coronavirus drug shows limited benefit in moderately ill patients - Business Insider

slipped 4% on Monday after a late-stage coronavirus drug trial showed that remdesivir had limited success treating moderately ill patients.

The company said that remdesivir helped patients in the trial with "moderate" disease recover more quickly when they took it for five days but it had limited benefits for patients who took it for 10 days. Gilead said patients in the group that received remdesivir for five days were 65% more likely to show signs of clinical improvement compared to those who got usual care, without receiving the drug.

Remdesivir has been tested as a treatment for patients with COVID-19. It has been authorized for emergency use by the US Food and Drug Administration and has been approved for use in Japan. While Monday's results affirm that remdesivir does have some success in treating COVID-19 it may raise questions how beneficial it will be overall.

Fauci hardest hit

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

YouTube at 15: The inside story of YouTube's history - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web. $THETA You left out the part how YouTube helped amplify white supremacists, flat earthers, anti-vaxxers, and other dangerous nutjobs, all for money to the detriment of society. 15 years to build one of the most detestable piles of shit ever unleashed on society
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »